Keros Therapeutics, Inc.
Keros Therapeutics, Inc. (KROS): 10 pipeline candidates · 1 upcoming catalyst · ~243 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
242.5 months
D/E 0.09 · 0% dilution
Lead: Phase 3
10 candidates
1 upcoming, next in ~3826d
3 buys · 5 sells (180d)
A transparent, data-derived signal for Keros Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$203.7M
Cash
$282.9M
Quarterly Burn
$3.5M
Runway
242.5 mo
Revenue
$32K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| cibotercept (KER-012) | Phase 2 |
| Efruxifermin | Phase 3 |
| elritercept (KER-050) | Phase 3 |
| Esomeprazole | Phase 1 |
| JTE-162 | Phase 1 |
| JTT-861 Capsules | Phase 2 |
| KER-065 | Phase 1 |
| NX-5948 | Phase 1 |
| rinvatercept | Phase 1 |
| TAK-226 | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
147
Total value held
$184.8M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,411,793 | $26.6M |
| vanguard capital management llc | 1,662,842 | $18.4M |
| orbimed advisors llc | 759,155 | $8.4M |
| jacobs levy equity management, inc | 706,071 | $7.8M |
| federated hermes, inc. | 689,229 | $7.6M |
| vanguard portfolio management llc | 682,043 | $7.5M |
| geode capital management, llc | 681,460 | $7.5M |
| arrowstreet capital, limited partnership | 590,249 | $6.5M |
| state street corp | 561,730 | $6.2M |
| citadel advisors llc | 553,766 | $6.1M |
Showing top 10 of 147 institutional holders of Keros Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Keros Therapeutics, Inc.'s pipeline?
Keros Therapeutics, Inc. (KROS) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Keros Therapeutics, Inc.'s lead drug candidate?
Keros Therapeutics, Inc.'s most advanced tracked candidate is cibotercept (KER-012) (Phase 2) for Pulmonary arterial hypertension (PAH); cardiovascular disorders.
What is Keros Therapeutics, Inc.'s next catalyst?
Keros Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ESOMEPRAZOLE MAGNESIUM" — expected December 8, 2036.
What is Keros Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Keros Therapeutics, Inc. has approximately 242.5 months of cash runway.
What is Keros Therapeutics, Inc.'s market capitalization?
Keros Therapeutics, Inc.'s market capitalization is approximately $203.7M.
Get the full picture on Keros Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.